Ceraxon, 100 mg/ml 10 ml 10 pcs

Ceraxone is a nootropic drug.

Cyticolin, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: promotes the repair of damaged cell membranes, inhibits the action of phospholipases, preventing the excessive formation of free radicals, and also prevents cell death by acting on apoptosis mechanisms.

In the acute period of stroke, citicoline reduces the volume of brain tissue damage and improves cholinergic transmission.

In craniocerebral trauma reduces the duration of post-traumatic coma and severity of neurological symptoms, moreover, citicoline helps to reduce the duration of recovery period.

In chronic cerebral hypoxia citicoline is effective in treating cognitive disorders such as memory impairment, lack of initiative, difficulties in performing daily activities and self-care. It increases the level of attention and consciousness and reduces the manifestation of amnesia.

Ceraxone^® is effective in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.

Indications

Acute period of ischemic stroke (as part of complex therapy);
recovery period of ischemic and hemorrhagic strokes;
TBI, acute (as part of complex therapy) and recovery period;
cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

Pharmacological effect

Ceraxon is a nootropic drug.

Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action: it promotes the restoration of damaged cell membranes, inhibits the action of phospholipases, preventing the excessive formation of free radicals, and also prevents cell death by affecting the mechanisms of apoptosis.

In the acute period of stroke, citicoline reduces the volume of brain tissue damage and improves cholinergic transmission.

In case of traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms; in addition, citicoline helps to reduce the duration of the recovery period.

In chronic cerebral hypoxia, citicoline is effective in the treatment of cognitive disorders such as memory impairment, lack of initiative, and difficulties in performing daily activities and self-care. Increases the level of attention and consciousness, and also reduces the manifestation of amnesia.

Ceraxon® is effective in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.

Special instructions

During the treatment period, care should be taken when performing potentially hazardous activities that require special attention and quick reactions (driving a car and other vehicles, working with moving mechanisms, working as a dispatcher and operator, etc.).

Oral solution (optional).

In the cold, a small amount of crystals may form due to temporary partial crystallization of the preservative.

With further storage under recommended conditions, the crystals dissolve within several months.

The presence of crystals does not affect the quality of the drug.

Active ingredient

Citicoline

Composition

1 ml of oral solution contains:

active substance:
citicoline sodium (equivalent to 100 mg citicoline)
excipients:
sorbitol – 200 mg;
glycerol – 50 mg;
methyl parahydroxybenzoate – 1.45 mg;
propyl parahydroxybenzoate – 0.25 mg;
sodium citrate dihydrate – 6 mg;
sodium saccharinate – 0.2 mg;
strawberry flavor (strawberry essence 1487-S-Lucta) – 0.408 mg;
potassium sorbate – 3 mg;
citric acid 50% solution – to pH 6;
purified water – up to 1 ml.

Pregnancy

There are no sufficient data on the use of citicoline in pregnant women.

Although animal studies have not revealed any negative effects, during pregnancy the drug Ceraxon® is prescribed only in cases where the expected benefit to the mother outweighs the potential risk to the fetus.

When prescribing Ceraxon® during lactation, women should stop breastfeeding, since there is no data on the excretion of citicoline in human milk.

Contraindications

Hypersensitivity to any of the components of the drug;
pronounced vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system);
rare hereditary diseases associated with fructose intolerance;
children under 18 years of age (due to the lack of sufficient clinical data).

Side Effects

Very rare (less than 1/10,000) (including individual cases): allergic reactions (rash, itching, anaphylactic shock), headache, dizziness, feeling of heat, tremor, nausea, vomiting, diarrhea, hallucinations, swelling, shortness of breath, insomnia, agitation, loss of appetite, numbness in paralyzed limbs, changes in the activity of liver enzymes.

In some cases, Ceraxon® can stimulate the parasympathetic system and also cause a short-term change in blood pressure.

If any of the side effects indicated in the instructions get worse, or any other side effects not listed in the instructions are noticed, you should inform your doctor.

Interaction

Citicoline may increase the effects of levodopa on the body.

Treatment with Ceraxon is not carried out at the same time as medications that contain meclofenoxate.

Overdose

Given the low toxicity of the drug, cases of overdose have not been described.

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

3 years

Manufacturer

Ferrer International S.A., Spain